Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) CFO Edward H. Myles sold 9,458 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $8.98, for a total transaction of $84,932.84. Following the completion of the sale, the chief financial officer now directly owns 201,518 shares of the company’s stock, valued at $1,809,631.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Scholar Rock Stock Performance
Shares of NASDAQ:SRRK opened at $8.49 on Thursday. Scholar Rock Holding Co. has a 12-month low of $5.93 and a 12-month high of $21.17. The stock has a fifty day simple moving average of $12.24 and a two-hundred day simple moving average of $14.85. The company has a current ratio of 6.58, a quick ratio of 6.58 and a debt-to-equity ratio of 0.24.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.11). During the same period in the prior year, the company posted ($0.46) EPS. As a group, equities research analysts expect that Scholar Rock Holding Co. will post -2.4 EPS for the current fiscal year.
Institutional Investors Weigh In On Scholar Rock
Analyst Ratings Changes
SRRK has been the subject of a number of research reports. Truist Financial reissued a “buy” rating and issued a $20.00 price target on shares of Scholar Rock in a research note on Wednesday, April 3rd. BMO Capital Markets raised their target price on Scholar Rock from $29.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, June 13th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Scholar Rock in a research report on Tuesday, June 4th. Wedbush reiterated an “outperform” rating and issued a $23.00 price objective on shares of Scholar Rock in a report on Tuesday, May 7th. Finally, Raymond James assumed coverage on shares of Scholar Rock in a report on Thursday, March 28th. They set a “strong-buy” rating and a $30.00 target price on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $26.00.
Get Our Latest Analysis on Scholar Rock
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Featured Stories
- Five stocks we like better than Scholar Rock
- How to Calculate Options Profits
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- 3 Healthcare Dividend Stocks to Buy
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.